Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
Raja Prince, Founder and BOD of BLEEDnFIRE Therapeutics, shared BLEEDnFIRE Therapeutics‘ post on LinkedIn:
“Excited to present our latest research on Protein S silencing in FXI deficiency, von Willebrand disease and hemophilic arthropathies, together with Rim Diab and Siavash Rahimi at SOHC 2026!
Proud to share this moment highlighting our collective efforts to advance innovative therapies for bleeding disorders.
Looking forward to inspiring discussions!”
BLEEDnFIRE Therapeutics shared a post on LinkedIn:
“On Wednesday, November 18, the team will present three studies on Protein S at the Swiss Oncology and Hematology Congress (SOHC) in Basel.
Rim Diab will present research on controlled Protein S expression as a strategy to rebalance haemostasis in factor XI deficiency.
Raja Prince will present research on using siRNA to modulate Protein S expression and rebalance haemostasis in von Willebrand disease.
Siavash Rahimi will present findings on how Protein S modulates synovial and myeloid responses in haemophilic arthropathy.
Congratulations to all three speakers on being selected for oral presentations.
Come join us on Wednesday, 18 November, at 10:30 in Kairo 1–2, Congress Center Basel.”

Stay updated with Hemostasis Today.
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance
-
Nov 19, 2026, 12:56Batool Abuhalimeh: The Hidden Psychological Burden of Pulmonary Embolism
-
Nov 19, 2026, 12:45Pedro Perez: PE Recovery – From Acute Treatment to Long-Term Follow-Up
-
Nov 19, 2026, 12:34Edward Lee Carter: Are We Ready for FXIa Inhibitors?
-
Nov 19, 2026, 12:19Essama Telli: When a Bruise Doesn’t Heal – Recognising the Warning Signs
-
Nov 19, 2026, 11:51Wolfgang Miesbach: Beyond Episomal Gene Therapy in Haemophilia B
-
Nov 19, 2026, 11:18A First Look at WFH CCS 2027